Oster HS - Search Results

1

Anemia as a risk factor for ischemic heart disease.

Zeidman A, Fradin Z, Blecher A, Oster HS, Avrahami Y, Mittelman M. Zeidman A, et al. Among authors: oster hs. Isr Med Assoc J. 2004 Jan;6(1):16-8. Isr Med Assoc J. 2004. PMID: 14740503 Free article.

2

Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies.

Mittelman M, Zeidman A, Kanter P, Katz O, Oster H, Rund D, Neumann D. Mittelman M, et al. Eur J Haematol. 2004 Mar;72(3):155-65. doi: 10.1046/j.0902-4441.2003.00190.x. Eur J Haematol. 2004. PMID: 14962233

3

Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?

Prutchi-Sagiv S, Golishevsky N, Oster HS, Katz O, Cohen A, Naparstek E, Neumann D, Mittelman M. Prutchi-Sagiv S, et al. Among authors: oster hs. Br J Haematol. 2006 Dec;135(5):660-72. doi: 10.1111/j.1365-2141.2006.06366.x. Br J Haematol. 2006. PMID: 17107348 Free article.

4

Erythropoietin in clinical practice: current use, effect on survival, and future directions.

Oster HS, Hoffman M, Prutchi-Sagiv S, Katz O, Neumann D, Mittelman M. Oster HS, et al. Isr Med Assoc J. 2006 Oct;8(10):703-6. Isr Med Assoc J. 2006. PMID: 17125118 Free article. Review.

5

The lower risk MDS patient at risk of rapid progression.

Mittelman M, Oster HS, Hoffman M, Neumann D. Mittelman M, et al. Among authors: oster hs. Leuk Res. 2010 Dec;34(12):1551-5. doi: 10.1016/j.leukres.2010.05.023. Epub 2010 Jun 22. Leuk Res. 2010. PMID: 20573398 Review.

6

Erythropoietin: the swinging pendulum.

Oster HS, Neumann D, Hoffman M, Mittelman M. Oster HS, et al. Leuk Res. 2012 Aug;36(8):939-44. doi: 10.1016/j.leukres.2012.04.017. Epub 2012 May 11. Leuk Res. 2012. PMID: 22579365 Review.

7

Erythropoietin treatment is associated with an augmented immune response to the influenza vaccine in hematologic patients.

Oster HS, Prutchi-Sagiv S, Halutz O, Shabtai E, Hoffman M, Neumann D, Mittelman M. Oster HS, et al. Exp Hematol. 2013 Feb;41(2):167-71. doi: 10.1016/j.exphem.2012.10.011. Epub 2012 Oct 26. Exp Hematol. 2013. PMID: 23107605 Free article. Clinical Trial.

8

Mortality in heart failure with worsening anemia: a national study.

Oster HS, Benderly M, Hoffman M, Cohen E, Shotan A, Mittelman M. Oster HS, et al. Isr Med Assoc J. 2013 Jul;15(7):368-72. Isr Med Assoc J. 2013. PMID: 23943983 Free article.

9

Immunosuppressive Therapy in Myelodysplastic Syndromes Is Still Alive.

Mittelman M, Oster HS. Mittelman M, et al. Among authors: oster hs. Acta Haematol. 2015;134(3):135-7. doi: 10.1159/000371833. Epub 2015 Apr 24. Acta Haematol. 2015. PMID: 25925850 No abstract available.

10

Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.

Mittelman M, Filanovsky K, Ofran Y, Rosenbaum H, Raanani P, Braester A, Goldschmidt N, Kirgner I, Herishanu Y, Perri C, Ellis M, Oster HS; Israel Myelodysplastic Syndrome Working Group (MDS-WG). Mittelman M, et al. Among authors: oster hs. Ann Hematol. 2016 Oct;95(11):1811-8. doi: 10.1007/s00277-016-2776-x. Epub 2016 Aug 22. Ann Hematol. 2016. PMID: 27546027 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

37 results

Search Page